Literature DB >> 25264572

Antibody mimetics: promising complementary agents to animal-sourced antibodies.

Abdul Rasheed Baloch1, Abdul Wahid Baloch2, Brian J Sutton3, Xiaoying Zhang1.   

Abstract

Despite their wide use as therapeutic, diagnostic and detection agents, the limitations of polyclonal and monoclonal antibodies have inspired scientists to design the next generation biomedical agents, so-called antibody mimetics that offer many advantages over conventional antibodies. Antibody mimetics can be constructed by protein-directed evolution or fusion of complementarity-determining regions through intervening framework regions. Substantial progress in exploiting human, butterfly (Pieris brassicae) and bacterial systems to design and select mimetics using display technologies has been made in the past 10 years, and one of these mimetics [Kalbitor® (Dyax)] has made its way to market. Many challenges lie ahead to develop mimetics for various biomedical applications, especially those for which conventional antibodies are ineffective, and this review describes the current characteristics, construction and applications of antibody mimetics compared to animal-sourced antibodies. The possible limitations of mimetics and future perspectives are also discussed.

Entities:  

Keywords:  Antibody mimetics; diagnostics; monoclonal antibodies (mAbs); protein engineering; therapeutics

Mesh:

Substances:

Year:  2014        PMID: 25264572     DOI: 10.3109/07388551.2014.958431

Source DB:  PubMed          Journal:  Crit Rev Biotechnol        ISSN: 0738-8551            Impact factor:   8.429


  6 in total

1.  Derivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein Scaffold.

Authors:  Anna V Lomonosova; Andrei B Ulitin; Alexei S Kazakov; Tajib A Mirzabekov; Eugene A Permyakov; Sergei E Permyakov
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

2.  The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.

Authors:  Sami El Khatib; Mohamed Salla
Journal:  Leuk Res Rep       Date:  2022-06-27

Review 3.  Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.

Authors:  Nneka Pu Korie; Kwesi Z Tandoh; Samuel K Kwofie; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-17

4.  Generation and evaluation of IgY-scFv based mimetics against canine parvovirus.

Authors:  Shikun Ge; Xingxing Zhang; Fagang Zhong; Xiang Liu; Xiaoying Zhang
Journal:  Vet Res       Date:  2021-05-13       Impact factor: 3.683

5.  Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus.

Authors:  Shikun Ge; Rao Wu; Tingting Zhou; Xiang Liu; Jin Zhu; Xiaoying Zhang
Journal:  AMB Express       Date:  2022-02-12       Impact factor: 3.298

6.  Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold.

Authors:  Anna V Lomonosova; Elena V Ovchinnikova; Alexei S Kazakov; Alexander I Denesyuk; Alexander D Sofin; Roman V Mikhailov; Andrei B Ulitin; Tajib A Mirzabekov; Eugene A Permyakov; Sergei E Permyakov
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.